NextCure, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
NextCure announced a definitive all-stock merger agreement with Avere Therapeutics (July 14, 2026), expected to close H2 2026. Avere will simultaneously raise ~$320M in private financing. NextCure stockholders will receive contingent value rights (CVRs) tied to legacy assets; the combined company will trade as AVRX. NextCure halted SIM0505 enrollment, transferred LNCB74 to LigaChem as sole developer (retaining milestone/royalty rights), and took $5.1M asset impairment charge. Cash declined from $41.8M (Dec 31, 2025) to $20.1M (June 30, 2026).
Why this rating
All-stock merger with $320M equity raise is transformational for $12.6M market-cap company. Company ceases to exist as standalone entity; shareholders diluted but retain CVR upside. Business-changing.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.